Utilizing of 4-(benzothiazol-2-yl)phenylamine as a precursor of bioactive agents

A.Shaaban, Mohamed; M.Al Badry, Ossama; M.Kamal, Aliaa; A.Abd El-Gawad, Mohamd

MSAR Home
→
MSA University Academic Research
→
Research Papers, Articles and Books Chapters.
→
Faculty Of Pharmacy Research Paper
→
View Item

dc.contributor.author	A.Shaaban, Mohamed
dc.contributor.author	M.Al Badry, Ossama
dc.contributor.author	M.Kamal, Aliaa
dc.contributor.author	A.Abd El-Gawad, Mohamd
dc.date.accessioned	2019-10-21T07:19:31Z
dc.date.available	2019-10-21T07:19:31Z
dc.date.issued	2012
dc.identifier.citation	[1] T.D.Bradshaw, M.F.G.Stevens, A.D.Westwell; Current Med.Chem., 8, 203-210 (2001). [2] A.Monks, E.Harris, C.Hose, J.Connelly, E.A.Sausville; Molecular Pharmacology, 63, 766- 772 (2003). [3] E.Brantley, V.Trapani, M.C.Alley, C.D.Hose, T.D.Bradshaw, M.F.G.Stevens, E.A.Sausville, S.F.Stinson; DrugMetabolismandDisposition, 32, 1392-1401 (2004). [4] A.Waliqvist, J.Connelly, E.A.Sausville,D.G.Covell, A.Monks; Molecular Pharmacology, 69, 737-748 (2006). [5] C.O.Leong, M.Suggitt, D.J.Swaine, M.C.Bibby, M.F.G.Stevens, T.D.Bradshaw; Molecular Cancer Therapeutics, 3, 1585-1592 (2004). [6] Y.W.Chen, J.E.Cleaver, F.Hanaoka, C.F.Chang; K.Chou; Molecular Cancer Research, 4, 257-265 (2006). [7] E.L.Luzina, A.V.Popov; Eur.J.Med.Chem., 44, 4944-4953 (2009). [8] B.Soni, M.S.Ranawat, R.Sharma, A.Bhandari, S.Sharma; Eur.J.Med.Chem., 45, 2938-2942 (2010). [9] S.Bondock,W.Fadaly,M.A.Metwally; Eur.J.Med. Chem., 45, 3692-3701 (2010). [10] S.Bondock,W.Fadaly,M.A.Metwally; Eur.J.Med. Chem., 44, 4813-4818 (2009). [11] A.E.Rashad, A.H.Shamroukh, M.I.Hegab, H.M.Awad; Acta Chim.Slov., 52, 429-434 (2005). [12] M.Cacic, M.Trkovnik, F.Cacic, E.H.Schon; Molecules, 11, 134-147 (2006). [13] N.Agarwal, P.Srivastava, S.K.Raghuwanshi, D.N.Upadhyay, S.Smha, P.K.Shukia, V.Ram; J.Bioorg.Med.Chem., 10, 869-874 (2002). [14] P.Sharma,A.Kumar,M.Sharma; Eur.J.Med.Chem., 41, 833-840 (2006). [15] P.Vicini, A.Geronikaki, K.Anastasia, M.Incerti, F.Zam; Bioorg.Med.Chem., 14, 3859-3864 (2006). [16] S.Bondock, W.Khalifa, A.A.Fadda; Eur.J.Med. Chem., 42, 948-954 (2007). [17] V.Patil, K.Tilekar, S.Mehendale-Munj, R.Mohan, C.S.Ramaa; Eur.J.Med.Chem., 45, 4539-4544 (2010). [18] D.Havrylyuk, L.Mosula, B.Zimenkovsky, O.Vasylenko,A.Gzella,R.Lesyk; Eur.J.Med.Chem., 45, 5012-5021 (2010). [19] T.Kline, K.C.Barry, S.R.Jackson, H.B.Felise, H.V.Nguyen, S.I.Miller; Bioorg.Med.Chem.Lett., 19, 1340-1343 (2009). [20] S.P.Mohammed; Bull.Fac.Pharm.Cairo Uinv., 37, 33-40 (1999). [21] S.E.Abbas, M.M.Hanna, A.H.Abou Sier, M.A.H.Ramadan; Egypt J.Pharm.Sci., 34, 195-205 (1993). [22] B.Kahveci, O.Bekircan, S.A.Karaoghlu; Indain J.Chem.B, 44b, 2614-2617 (2005). [23] O.Pintilie, L.Profire,V.Sunel,M.Popa,A.Pui;Molecules, 12, 103-113 (2007). [24] M.A.Shaaban, O.M.Al Badry, A.M.Kamal, M.A.W.Abd El-Gawad; J.Chem.Reseach, 4, 715- 718 (2008). [25] G.Bruno, L.Costantino, C.Curinga, R.Maccari, F.Monforte, F.Nicolo , R.Ottana , M.G.Vigoritac; Bioorg.Med.Chem., 10, 1077-1084 (2002). [26] R.Ottana , R.Maccari, M.L.Barreca, G.Bruno, A.Rotondo, A.Rossi, G.Chiricosta, R.Di Paola, L.Sautebin, S.Cuzzocrea, M.G.Vigorita; Bioorg. Med.Chem., 13, 4243-4252 (2005). [27] T.O.Richardson,V.P.Shambhag, K.Adair, S.Smith; J.Heterocyclic Chem., 35, 1301 (1998).	en_US
dc.identifier.issn	0974 - 7516
dc.identifier.other	https://doi.org/
dc.identifier.uri	https://t.ly/WE9rm
dc.description.abstract	Several heterocyclic compounds show either anticancer or antimicrobial activity, the intial goal of this study was directed towards combining some of those heterocyclic moieties- that have either activity- together to test whether the newly formed compounds will demonstrate both activity or one activity will predominate over the other or both activity will deminish. This was accomplished via Scheme 1 and Scheme 2 where diazotization of 4-(benzothiazol-2-yl)phenylamine 1 followed by reacting this functionalized hydrazone with a variety of binucleophiles to give the key intermediates that reacted with amino reagents viz. hydrazine, urea or thiourea to yield some of the goal compounds (Scheme 1). Reacting compound 1with carbonyl or isothiocyanate reagents followed by cyclization of the given key intermediates afforeded a set of novel target compounds (Scheme 2). These final compunds were tested for in vitro antimicrobial and anticancer activity. Two compounds showed both antimicrobial and anticancer activity while the other compounds were highly active either as antimicrobial only or as anticancer only.	en_US
dc.description.sponsorship	Organic CHEMISTRY	en_US
dc.language.iso	en	en_US
dc.publisher	Organic CHEMISTRY	en_US
dc.relation.ispartofseries	Organic CHEMISTRY;Volume 8 Issue 9
dc.subject	benzothiazol	en_US
dc.subject	phenylamine	en_US
dc.subject	Pharmacophores	en_US
dc.subject	Anticancer	en_US
dc.subject	Antimicrobial	en_US
dc.subject	Improving chemotherapy regimen design	en_US
dc.title	Utilizing of 4-(benzothiazol-2-yl)phenylamine as a precursor of bioactive agents	en_US
dc.type	Article	en_US
dc.identifier.doi	https://doi.org/
dc.Affiliation	October University for modern sciences and Arts (MSA)